NO330278B1 - Anvendelse av en CC-kjemokinmutant i fremstillingen av en farmasoytisk sammensetning til behandlingen av multippel sklerose og/eller andre demyelinerende sykdommer, farmasoytisk sammensetning omfattende mutantene, trunkert og mutert human RANTES og rekombinant fremgangsmate for fremstilling av samme,DNA-molekyl som koder for dette, ekspresjonsvektor som omfatter DNA-molekylet og vertscelle som omfatter ekspresjonsvektoren - Google Patents
Anvendelse av en CC-kjemokinmutant i fremstillingen av en farmasoytisk sammensetning til behandlingen av multippel sklerose og/eller andre demyelinerende sykdommer, farmasoytisk sammensetning omfattende mutantene, trunkert og mutert human RANTES og rekombinant fremgangsmate for fremstilling av samme,DNA-molekyl som koder for dette, ekspresjonsvektor som omfatter DNA-molekylet og vertscelle som omfatter ekspresjonsvektoren Download PDFInfo
- Publication number
- NO330278B1 NO330278B1 NO20031525A NO20031525A NO330278B1 NO 330278 B1 NO330278 B1 NO 330278B1 NO 20031525 A NO20031525 A NO 20031525A NO 20031525 A NO20031525 A NO 20031525A NO 330278 B1 NO330278 B1 NO 330278B1
- Authority
- NO
- Norway
- Prior art keywords
- rantes
- mutant
- pharmaceutical composition
- expression vector
- dna molecule
- Prior art date
Links
- 201000006417 multiple sclerosis Diseases 0.000 title claims description 19
- 238000011282 treatment Methods 0.000 title claims description 19
- 102000001902 CC Chemokines Human genes 0.000 title claims description 14
- 108010040471 CC Chemokines Proteins 0.000 title claims description 14
- 108020004414 DNA Proteins 0.000 title claims description 12
- 208000016192 Demyelinating disease Diseases 0.000 title claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 8
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 title claims description 7
- 239000013604 expression vector Substances 0.000 title claims description 7
- 102000045341 human CCL5 Human genes 0.000 title claims description 7
- 102000053602 DNA Human genes 0.000 title claims description 6
- 238000002360 preparation method Methods 0.000 title claims description 3
- 238000010188 recombinant method Methods 0.000 title claims description 3
- 108010055166 Chemokine CCL5 Proteins 0.000 claims description 90
- 102000001327 Chemokine CCL5 Human genes 0.000 claims description 90
- 102000019034 Chemokines Human genes 0.000 claims description 32
- 108010012236 Chemokines Proteins 0.000 claims description 32
- 230000027455 binding Effects 0.000 claims description 21
- 230000035772 mutation Effects 0.000 claims description 10
- 239000004480 active ingredient Substances 0.000 claims description 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 7
- 125000002091 cationic group Chemical group 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 101710151805 Mitochondrial intermediate peptidase 1 Proteins 0.000 claims description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 2
- 239000001963 growth medium Substances 0.000 claims description 2
- 229920001184 polypeptide Polymers 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 26
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 23
- 229920000669 heparin Polymers 0.000 description 20
- 229960002897 heparin Drugs 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 19
- 108090000623 proteins and genes Proteins 0.000 description 17
- 102000004169 proteins and genes Human genes 0.000 description 16
- 238000003556 assay Methods 0.000 description 14
- 235000018102 proteins Nutrition 0.000 description 14
- 239000011780 sodium chloride Substances 0.000 description 14
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 230000003993 interaction Effects 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 206010033799 Paralysis Diseases 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 238000007912 intraperitoneal administration Methods 0.000 description 9
- 230000007115 recruitment Effects 0.000 description 9
- 235000001014 amino acid Nutrition 0.000 description 8
- 230000001413 cellular effect Effects 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 210000004379 membrane Anatomy 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 210000001616 monocyte Anatomy 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 150000001413 amino acids Chemical group 0.000 description 7
- 239000012148 binding buffer Substances 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 6
- 108010023347 Met- RANTES Proteins 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000007983 Tris buffer Substances 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 6
- 102100031172 C-C chemokine receptor type 1 Human genes 0.000 description 5
- 101710149814 C-C chemokine receptor type 1 Proteins 0.000 description 5
- 229920002683 Glycosaminoglycan Polymers 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 230000006041 cell recruitment Effects 0.000 description 5
- 201000002491 encephalomyelitis Diseases 0.000 description 5
- 230000028550 monocyte chemotaxis Effects 0.000 description 5
- 238000000159 protein binding assay Methods 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 4
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 4
- 208000031886 HIV Infections Diseases 0.000 description 4
- 208000037357 HIV infectious disease Diseases 0.000 description 4
- 241000235058 Komagataella pastoris Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 102000008300 Mutant Proteins Human genes 0.000 description 4
- 108010021466 Mutant Proteins Proteins 0.000 description 4
- 229920002684 Sepharose Polymers 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 235000004279 alanine Nutrition 0.000 description 4
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 208000010726 hind limb paralysis Diseases 0.000 description 4
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 238000001525 receptor binding assay Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- CWERGRDVMFNCDR-UHFFFAOYSA-M thioglycolate(1-) Chemical compound [O-]C(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-M 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 3
- 108700012434 CCL3 Proteins 0.000 description 3
- 102000000013 Chemokine CCL3 Human genes 0.000 description 3
- 206010012305 Demyelination Diseases 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 229920001917 Ficoll Polymers 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- 229920002971 Heparan sulfate Polymers 0.000 description 3
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 3
- 108010081690 Pertussis Toxin Proteins 0.000 description 3
- 102000016611 Proteoglycans Human genes 0.000 description 3
- 108010067787 Proteoglycans Proteins 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 238000005277 cation exchange chromatography Methods 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000035605 chemotaxis Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 3
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 231100000350 mutagenesis Toxicity 0.000 description 3
- 238000002703 mutagenesis Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000002821 scintillation proximity assay Methods 0.000 description 3
- 239000001632 sodium acetate Substances 0.000 description 3
- 235000017281 sodium acetate Nutrition 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 238000011725 BALB/c mouse Methods 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 2
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102100026720 Interferon beta Human genes 0.000 description 2
- 108090000467 Interferon-beta Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 208000008457 Neurologic Manifestations Diseases 0.000 description 2
- 241000235648 Pichia Species 0.000 description 2
- 239000012979 RPMI medium Substances 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 230000009809 T cell chemotaxis Effects 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- LPQOADBMXVRBNX-UHFFFAOYSA-N ac1ldcw0 Chemical compound Cl.C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3CCSC1=C32 LPQOADBMXVRBNX-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000003050 axon Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 210000001638 cerebellum Anatomy 0.000 description 2
- 230000003399 chemotactic effect Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000012875 competitive assay Methods 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 230000005713 exacerbation Effects 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 238000002595 magnetic resonance imaging Methods 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 208000010713 partial hind limb paralysis Diseases 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 229940071127 thioglycolate Drugs 0.000 description 2
- 210000001364 upper extremity Anatomy 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 238000007809 Boyden Chamber assay Methods 0.000 description 1
- 102100023701 C-C motif chemokine 18 Human genes 0.000 description 1
- 102100036850 C-C motif chemokine 23 Human genes 0.000 description 1
- 102100032366 C-C motif chemokine 7 Human genes 0.000 description 1
- 101710155834 C-C motif chemokine 7 Proteins 0.000 description 1
- 102220573491 C-C motif chemokine 7_K45A_mutation Human genes 0.000 description 1
- 102100034871 C-C motif chemokine 8 Human genes 0.000 description 1
- 101710155833 C-C motif chemokine 8 Proteins 0.000 description 1
- 108050006947 CXC Chemokine Proteins 0.000 description 1
- 102000019388 CXC chemokine Human genes 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 108010082155 Chemokine CCL18 Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 108010053070 Glutathione Disulfide Proteins 0.000 description 1
- 101000713081 Homo sapiens C-C motif chemokine 23 Proteins 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 102100023487 Lens fiber major intrinsic protein Human genes 0.000 description 1
- 102220553626 Lens fiber major intrinsic protein_R47A_mutation Human genes 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 102220608644 Methyl-CpG-binding domain protein 1_R44K_mutation Human genes 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 230000031902 chemoattractant activity Effects 0.000 description 1
- 239000002559 chemokine receptor antagonist Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 238000011210 chromatographic step Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 230000007396 fibrous gliosis Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 1
- 150000002337 glycosamines Chemical class 0.000 description 1
- 210000004884 grey matter Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 229960001388 interferon-beta Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 208000027905 limb weakness Diseases 0.000 description 1
- 231100000861 limb weakness Toxicity 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- AEUKDPKXTPNBNY-XEYRWQBLSA-N mcp 2 Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)C1=CC=CC=C1 AEUKDPKXTPNBNY-XEYRWQBLSA-N 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 210000001259 mesencephalon Anatomy 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 230000002784 sclerotic effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 108010059339 submandibular proteinase A Proteins 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
- C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00121665 | 2000-10-04 | ||
| PCT/EP2001/011428 WO2002028419A2 (en) | 2000-10-04 | 2001-10-03 | Chemokine mutants in the treatment of multiple sclerosis |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20031525L NO20031525L (no) | 2003-04-03 |
| NO20031525D0 NO20031525D0 (no) | 2003-04-03 |
| NO330278B1 true NO330278B1 (no) | 2011-03-21 |
Family
ID=8170011
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20031525A NO330278B1 (no) | 2000-10-04 | 2003-04-03 | Anvendelse av en CC-kjemokinmutant i fremstillingen av en farmasoytisk sammensetning til behandlingen av multippel sklerose og/eller andre demyelinerende sykdommer, farmasoytisk sammensetning omfattende mutantene, trunkert og mutert human RANTES og rekombinant fremgangsmate for fremstilling av samme,DNA-molekyl som koder for dette, ekspresjonsvektor som omfatter DNA-molekylet og vertscelle som omfatter ekspresjonsvektoren |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US7402303B2 (ko) |
| EP (1) | EP1326628B1 (ko) |
| JP (1) | JP3908165B2 (ko) |
| KR (1) | KR100837898B1 (ko) |
| CN (1) | CN1285381C (ko) |
| AR (1) | AR030854A1 (ko) |
| AT (1) | ATE265222T1 (ko) |
| AU (2) | AU2002215919B2 (ko) |
| BG (1) | BG66137B1 (ko) |
| BR (1) | BR0114407A (ko) |
| CA (1) | CA2423616C (ko) |
| CZ (1) | CZ303409B6 (ko) |
| DE (1) | DE60103078T2 (ko) |
| DK (1) | DK1326628T3 (ko) |
| EA (1) | EA006137B1 (ko) |
| EE (1) | EE05174B1 (ko) |
| ES (1) | ES2217199T3 (ko) |
| HK (1) | HK1062811A1 (ko) |
| HR (1) | HRP20030215B1 (ko) |
| HU (1) | HUP0302194A3 (ko) |
| IL (2) | IL155178A0 (ko) |
| MX (1) | MXPA03003008A (ko) |
| NO (1) | NO330278B1 (ko) |
| PL (1) | PL204231B1 (ko) |
| PT (1) | PT1326628E (ko) |
| RS (1) | RS50738B (ko) |
| SI (1) | SI1326628T1 (ko) |
| SK (1) | SK287523B6 (ko) |
| UA (1) | UA77950C2 (ko) |
| WO (1) | WO2002028419A2 (ko) |
| ZA (1) | ZA200302315B (ko) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005525089A (ja) | 2001-12-17 | 2005-08-25 | アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ | ケモカイン・アンタゴニストとして作用するケモカイン突然変異体 |
| DE60303929T2 (de) * | 2002-04-04 | 2006-08-10 | Applied Research Systems Ars Holding N.V. | Chemokin-muntanten mit verbesserter oraler bioverfügbarkeit |
| WO2004062688A2 (en) * | 2002-12-23 | 2004-07-29 | Applied Research Systems Ars Holding N.V. | Use of cc-chemokine mutants against liver diseases |
| DE602004018014D1 (de) * | 2003-10-22 | 2009-01-08 | Serono Lab | Cxcl8-antagonisten |
| AT412785B (de) * | 2003-12-04 | 2005-07-25 | Kungl Andreas J Dr | Gag-bindungsproteine |
| DE60304435T2 (de) * | 2004-01-19 | 2006-08-24 | Ares Trading S.A. | Verfahren zur Reinigung von in Bakterien exprimierten Proteinen |
| GB0412400D0 (en) * | 2004-06-03 | 2004-07-07 | Univ Newcastle | Treatment of inflammatory conditions |
| EP1760110B1 (en) * | 2005-09-03 | 2011-11-02 | Samsung SDI Co., Ltd. | Polybenzoxazine-based compound, electrolyte membrane including the same, and fuel cell employing the electrolyte membrane |
| GB0614755D0 (en) | 2006-07-25 | 2006-09-06 | Univ Geneve | Cytokine derivatives |
| MX2010001307A (es) | 2007-08-02 | 2010-07-30 | Novimmune Sa | Anticuerpos anti-proteína regulada con la activación, expresada y secretada por los linfocitos t normales y metodos de uso de los mismos. |
| AU2011213559B2 (en) * | 2010-02-08 | 2015-05-07 | The Trustees Of The University Of Pennsylvania | Nucleic acid molecules encoding RANTES, and compositions comprising and methods of using the same |
| CA3101052A1 (en) | 2018-05-28 | 2019-12-05 | ORION Biotechnology Switzerland Sarl | Methods of inhibiting cerebral inflammation |
| WO2022093857A1 (en) * | 2020-10-26 | 2022-05-05 | City Of Hope | Oncolytic virus compositions and methods for the treatment of cancer |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5739103A (en) * | 1993-11-12 | 1998-04-14 | Dana-Farber Cancer Institute | Chemokine N-terminal deletion mutations |
| WO1998006751A1 (en) * | 1996-08-16 | 1998-02-19 | Research Corporation Technologies, Inc. | Mcp-3, rantes and mip-1alpha receptor antagonists |
| EP0906954A1 (en) * | 1997-09-29 | 1999-04-07 | Applied Research Systems ARS Holding N.V. | Amino-terminal truncated c-c chemokines as chemokine antagonist |
| DE69832216T2 (de) * | 1997-12-23 | 2006-05-24 | Fondazione Centro San Raffaele Del Monte Tabor | RANTES-Mutanten und therapeutische Anwendungen davon |
| AU2740900A (en) * | 1999-01-29 | 2000-08-18 | Millennium Pharmaceuticals, Inc. | Method of treating demyelinating inflammatory disease using ccr1 antagonists |
-
2001
- 2001-03-10 UA UA2003044038A patent/UA77950C2/uk unknown
- 2001-10-03 AT AT01986265T patent/ATE265222T1/de active
- 2001-10-03 PT PT01986265T patent/PT1326628E/pt unknown
- 2001-10-03 PL PL362350A patent/PL204231B1/pl not_active IP Right Cessation
- 2001-10-03 AU AU2002215919A patent/AU2002215919B2/en not_active Ceased
- 2001-10-03 KR KR1020037004599A patent/KR100837898B1/ko not_active IP Right Cessation
- 2001-10-03 EP EP01986265A patent/EP1326628B1/en not_active Expired - Lifetime
- 2001-10-03 WO PCT/EP2001/011428 patent/WO2002028419A2/en active IP Right Grant
- 2001-10-03 EA EA200300439A patent/EA006137B1/ru not_active IP Right Cessation
- 2001-10-03 HU HU0302194A patent/HUP0302194A3/hu unknown
- 2001-10-03 CA CA2423616A patent/CA2423616C/en not_active Expired - Fee Related
- 2001-10-03 DK DK01986265T patent/DK1326628T3/da active
- 2001-10-03 MX MXPA03003008A patent/MXPA03003008A/es active IP Right Grant
- 2001-10-03 EE EEP200300139A patent/EE05174B1/xx not_active IP Right Cessation
- 2001-10-03 ES ES01986265T patent/ES2217199T3/es not_active Expired - Lifetime
- 2001-10-03 ZA ZA200302315A patent/ZA200302315B/en unknown
- 2001-10-03 DE DE60103078T patent/DE60103078T2/de not_active Expired - Lifetime
- 2001-10-03 JP JP2002532243A patent/JP3908165B2/ja not_active Expired - Fee Related
- 2001-10-03 BR BR0114407-3A patent/BR0114407A/pt not_active IP Right Cessation
- 2001-10-03 AU AU1591902A patent/AU1591902A/xx active Pending
- 2001-10-03 CN CNB018199178A patent/CN1285381C/zh not_active Expired - Fee Related
- 2001-10-03 CZ CZ20030947A patent/CZ303409B6/cs not_active IP Right Cessation
- 2001-10-03 US US10/398,457 patent/US7402303B2/en not_active Expired - Fee Related
- 2001-10-03 SK SK406-2003A patent/SK287523B6/sk not_active IP Right Cessation
- 2001-10-03 RS YUP-257/03A patent/RS50738B/sr unknown
- 2001-10-03 SI SI200130130T patent/SI1326628T1/xx unknown
- 2001-10-03 IL IL15517801A patent/IL155178A0/xx unknown
- 2001-10-04 AR ARP010104684A patent/AR030854A1/es unknown
-
2003
- 2003-03-20 HR HR20030215A patent/HRP20030215B1/xx not_active IP Right Cessation
- 2003-03-28 BG BG107685A patent/BG66137B1/bg unknown
- 2003-04-01 IL IL155178A patent/IL155178A/en not_active IP Right Cessation
- 2003-04-03 NO NO20031525A patent/NO330278B1/no not_active IP Right Cessation
-
2004
- 2004-08-02 HK HK04105657A patent/HK1062811A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4233214B2 (ja) | ケモカインアンタゴニストとしてのアミノ末端切除型ｒａｎｔｅｓ | |
| NO330278B1 (no) | Anvendelse av en CC-kjemokinmutant i fremstillingen av en farmasoytisk sammensetning til behandlingen av multippel sklerose og/eller andre demyelinerende sykdommer, farmasoytisk sammensetning omfattende mutantene, trunkert og mutert human RANTES og rekombinant fremgangsmate for fremstilling av samme,DNA-molekyl som koder for dette, ekspresjonsvektor som omfatter DNA-molekylet og vertscelle som omfatter ekspresjonsvektoren | |
| NO332309B1 (no) | Antagonister av CXCRX3-bindene CXC-kjemokiner, samt fremgangsmate for fremstilling derav, DNA molekyler kodende for nevnte antagonister, ekspresjonsvektor, vertcelle, farmasoytisk preparat og anvendelse av nevnte antagonister. | |
| AU2002215919A1 (en) | Chemokine mutants in the treatment of multiple sclerosis | |
| JP2006505243A (ja) | Ｍｃｐタンパク質の新規のアンタゴニスト | |
| AU2002358144B2 (en) | Chemokine mutants acting as chemokine antagonists | |
| AU711573B2 (en) | Short forms of chemokine beta-8 | |
| EP2578603A1 (en) | B cell activating factor antagonist and preparation method and use thereof | |
| US20030138400A1 (en) | Short forms of chemokine beta-8 | |
| JP2006516255A (ja) | 治療薬としてのｆ１１受容体（ｆ１１ｒ）拮抗薬 | |
| JP3621883B2 (ja) | ウイルスがコードするセマフォリンタンパク質受容体ｄｎａおよびポリペプチド | |
| CA2233367A1 (en) | Short forms of chemokine .beta.-8 | |
| MXPA00002881A (en) | Amino-terminally truncated rantes as chemokine antagonists | |
| MXPA98002380A (en) | Short shapes of bet chemiscino |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| CREP | Change of representative |
Representative=s name: ONSAGERS AS, POSTBOKS 6963 ST OLAVS PLASS, 0130 OS |
|
| MM1K | Lapsed by not paying the annual fees |